Real-world heart procedure blood thinner patterns under the microscope
NCT ID NCT05193019
First seen Feb 14, 2026
Summary
This study tracks how doctors in Spain use injectable blood thinners (cangrelor or GPIs) during heart procedures like stent placement. It includes 717 patients and will look at short-term outcomes like death, heart attack, stroke, and bleeding within 48 hours. The goal is to understand current practice and safety in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC HEART DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H.de Leon
León, 24080, Spain
-
Hospital Central de La Defensa Gómez Ulla
Madrid, 28047, Spain
-
Hospital Clinico Universitario Santiago de Compostela
Santiago de Compostela, 15706, Spain
-
Hospital Clinico Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital Universitari Joan Xxiii
Tarragona, 43005, Spain
-
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Hospital Universitario Lozano Blesa
Zaragoza, 50009, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, 39008, Spain
-
Hospital Universitario de Cabueñes
Gijón, 33394, Spain
-
Hospital Universitario de Cruces
Barakaldo, 48903, Spain
-
Hospital Universitario de Navarra
Pamplona, 31008, Spain
-
Hospital de Galdakao
Galdakao, 48960, Spain
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Parenteral antiplatelet agents (cangrelor or glycoprotein IIb/IIIa inhibitors)
What this could lead to
If successful, this could help doctors choose the best blood thinner for heart procedures, potentially reducing complications.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other countries or populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.